Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

3(50%)

Results Posted

0%(0 trials)

Terminated

1(17%)

Phase Distribution

Ph not_applicable

33%

Ph early_phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

3(60.0%)

N/ANon-phased studies

2(40.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Terminated(1)

Detailed Status

Recruiting3

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 13 (60.0%)

N/A2 (40.0%)

Trials by Status

completed233%

terminated117%

recruiting350%

Recent Activity

3 active trials

Showing 5 of 6

recruitingearly_phase_1

Cohort of Healthy People in Brain MRI, Together With a Language and Cognitive Assessment at the University Hospital of Nice

NCT04934033

completednot_applicable

Decoding Presymptomatic White Matter Changes in Huntington Disease

NCT03193099

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT06303921Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

Recruiting

NCT06932809Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

Recruiting

NCT06032026Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

Recruiting

NCT04934033Not Applicable

Cohort of Healthy People in Brain MRI, Together With a Language and Cognitive Assessment at the University Hospital of Nice

Completed

NCT03193099Not Applicable

Decoding Presymptomatic White Matter Changes in Huntington Disease

Completed

NCT01992029

Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis

Terminated

All 6 trials loaded

Drug Details

Intervention Type: BEHAVIORAL
Total Trials: 6